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Background: To report the efficacy and safety of salvage brachytherapy for seminal vesicle recurrence after initial
brachytherapy in a patient with prostate cancer. As far as we know, this is a first report of salvage brachytherapy for
seminal vesicle recurrence in Japan.
Case presentation: A 70-year-old Japanese man with low-risk prostate cancer received low-dose-rate brachytherapy.
Forty-two months after the seed implantation, he showed biochemical recurrence based on the nadir + 2 ng/mL
definition. The prostate specific antigen (PSA) level was 5.11 ng/mL at 58 months after seed implantation. A saturation
biopsy of the prostate showed no recurrence. Systemic screening also showed no distant metastases. However,
T2-weighted magnetic resonance imaging (MRI) demonstrated a low intensity area at the base of the right seminal
vesicle, which was strongly suggestive of recurrence. Sixty months after the initial therapy, a seminal vesicle biopsy
confirmed recurrence with a Gleason score of 4 + 3 before salvage brachytherapy was performed. The prescribed
dose was 145 Gy, the same as the dose of the initial therapy. One month later, the PSA level had rapidly declined to
0.898 ng/mL without androgen deprivation therapy. Ten months after the salvage brachytherapy, the PSA level reached
0.078 ng/mL. No adverse events were seen during the follow-up period.
Conclusions: We experienced a patient who was successfully treated with salvage brachytherapy for seminal vesicle
recurrence. Salvage brachytherapy is one of the promising therapeutic options for recurrence after initial brachytherapy.
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Several salvage therapeutic options including radical pros-
tatectomy, radiation therapy and androgen deprivation
therapy can be considered for patients who show sem-
inal vesicle recurrence after prostate brachytherapy. We
experienced a patient who underwent salvage brachy-
therapy. This is the first report of a case of salvage
brachytherapy for seminal vesicle recurrence after pros-
tate brachytherapy in Japan, as far as we know.* Correspondence: sendo@naramed-u.ac.jp
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A 70-year-old Japanese man underwent a medical checkup
in March 2005, which showed an abnormal prostate spe-
cific antigen (PSA) value (4.8 ng/mL), and he consulted a
urologist. He underwent needle biopsy of the prostate.
The histopathological findings indicated an adenocarcin-
oma with a Gleason score of 3 + 3. The number of positive
cores was 4 out of 8 cores (right lobe: 1/4, left lobe: 3/4).
The digital rectal examination showed no abnormal find-
ings. The clinical stage was T1cN0M0. In 2006, he under-
went a low-dose-rate brachytherapy (LDR-brachytherapy)
using a preplanning method and modified peripheral load-
ing at our hospital. The prescribed dose was 145 Gy. Re-
garding dosimetric parameters using CT images 1 month
after seed implantation, the minimal dose (Gy) received by
90% of the prostate gland (D90) was 183 Gy, the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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scribed minimal peripheral dose (V100) was 98.5%, and
the rectal volume (mL) that received 100% of the pre-
scribed dose (R100) was 0.02 mL. One year after seed im-
plantation, the PSA level reached the nadir at 0.38 ng/mL.
The PSA level then increased gradually. Forty-two months
later, PSA recurrence was confirmed based on the Phoenix
definition (nadir + 2 ng/mL). The patient was then ob-
served without any salvage therapy because the dosi-
metric quality of the initial therapy was excellent and
the possibility of PSA bounce was also considered.
Fifty-eight months after seed implantation, the PSA
level reached 5.11 ng/mL. A prostate saturation biopsy
demonstrated no obvious recurrence inside the pros-
tate. Systemic screening by lung and abdominal CT and
bone scan did not detect distant metastases. On the
other hand, T2-weighted and dynamic MRI images
demonstrated a low intensity area at the base of the
right seminal vesicle, which was very suspicious of re-
currence (Figure 1A,B,C). We proposed salvage prosta-
tectomy, salvage brachytherapy or androgen deprivation
therapy to the patient. Sixty months after the initial
therapy, he underwent salvage brachytherapy after pro-
viding informed consent. The prescribed dose of the sal-
vage therapy was 145 Gy as same as the initial therapy.
We used a radioactive source of 0.33 mC1 (13.1 MBq) for
salvage brachytherapy (as same as initial brachytherapy).
Prior to salvage brachytherapy, seminal vesicle biopsy was
performed and the histological findings showed an adeno-
carcinoma with a Gleason score of 4 + 3 at the base of the
right seminal vesicle. The base of right seminal vesicle was
set as the planning target volume (PTV) with 1 cm mar-
gin. Seven needles were inserted into the PTV, and 2 or 3
sources were implanted through each needle. Finally 20
sources were implanted by the real-time planning methodA B
Figure 1 MRI images of seminal vesicle recurrence. (A) T2-weighted imag
(B, C) Dynamic MRI also demonstrated a recurrence of seminal vesicle becaus
late phase.(Figure 2). Regarding dosimetric parameters using CT im-
ages 1 month after salvage brachytherapy, seminal vesicle
D90 was 280 Gy, seminal vesicle V100 was 100%, prostate
D90 was 206.4 Gy, prostate V100 was 99.2%, the R100 was
0.26 mL, and the minimal dose (Gy) received by 30% of
the urethra (UD30) was 285.7 Gy. The treatment time was
69 minutes. Since the PSA level rapidly decreased to
0.898 ng/mL by 1 month after seed implantation, he re-
ceived no adjuvant therapy. Ten months after seed im-
plantation, the PSA level reached 0.078 ng/mL. No
adverse events were seen during the follow-up period.
Discussion
When patients show PSA recurrence after LDR-
brachytherapy, there are several options for salvage
treatments such as androgen deprivation therapy, rad-
ical prostatectomy, radiation therapy, etc. A 70-year-old
Japanese man has a life-expectancy of 15.1 years if no
severe co-morbidities are present. We discussed the
merits and demerits of each modality of salvage therapy
with the patient. He finally chose salvage brachytherapy
of the seminal vesicle. There have been several previous
reports of salvage brachytherapy (Table 1). The onco-
logical outcomes showed a biochemical recurrence-free
rate of around 70%. Some patients have showed genito-
urinary and gastrointestinal adverse events of grade 3 or
greater, but the incidence rate was acceptable. Some re-
ports involved prescription of a full dose (145 Gy), while
the prescribed dose was reduced according to other re-
ports [1-7]. There is not a standard prescribed dose and
the pros and cons of adjuvant hormonal therapy are not
established. As far as we know, there are two reports of
salvage brachytherapy for seminal vesicle recurrence.
Koutrouveil et al. reported 31 patients who showed re-
currence after initial brachytherapy. Eleven of the 31C
e demonstrated a low-intensity area in the bottom of seminal vesicle.
e of an intensive enhancement in early phase and a washed-out in
A B
Figure 2 Pelvic X-ray and CT scan images after salvage brachytherapy. (A) Pelvic X-ray and (B) CT scan demonstrated the source at the
bottom of seminal vesicle.
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of these 11 patients showed no recurrence after salvage
brachytherapy. They also showed that salvage brachy-
therapy was as useful as other salvage therapies because
a high biochemical control rate (87%) was achieved [1].
Burri et al. also reported the results of salvage brachy-
therapy in 37 patients. They concluded that a PSA level
of less than 6 was a prognostic factor for salvage brachy-
therapy in multivariate analysis [2]. However, large-
scale studies on salvage brachytherapy have not been
published. Therefore, patient selection, optimal pre-
scribed dose, and use of adjuvant androgen deprivation
therapy are still controversial. The excessive dose area
of the seminal vesicle due to the small target volume
may consequently lead to the problem that the urethral
dose and the dose to the bottom of the prostate are aptTable 1 Several previous reports of salvage brachytherapy
Study year N Prior RT Use of ADT Median
f/u
Koutrouveils* 2003 [1] 31 seed Neo 3 mos
except 1
30 mos
Wong 2006 [3] 17 EBRT Neo 3 mos: 12
ad 6 mos: 5
44 mos
Nguyen 2007 [4] 25 EBRT: 13 seed: 12 none 47 mos
Lee 2007 [5] 21 EBRT Concurrent -ad: 12 36 mos
Aaronson 2009 [6] 24 EBRT Concurrent: 17% 30 mos
Moman 2010 [7] 31 EBRT: 20 seed: 11 Neo 3 mos: 5 9.2 yrs
Burri* 2010 [2] 37 EBRT: 32 seed: 5 Neo + ad 6 mos: 31 86 mos
*Report of brachytherapy for recurrence of seminal vesicle.
RT: Radiation Therapy, ADT: Androgen Deprivation Therapy, f/u: follow-up, EBRT : Ex
Neoadjuvant Therapy, Ad: Adjuvant Therapy, bDFS: biochemical Disease Free Surviv
GU: Genitourinary adverse effect, G: Grade.to be high. It is also difficult to insert needles into the
seminal vesicle because the distance from the perineum
to the seminal vesicle is longer than to the prostate for
seed implantation. With regard to the adverse events of
salvage brachytherapy, the RTOG 0526 study is pres-
ently in progress and the results are awaited. Our pa-
tient shows a favorable outcome at present during the
early stage after salvage therapy for seminal vesicle re-
currence. Longer follow-up data involving more pa-
tients are needed to establish the usefulness of salvage
brachytherapy, not only for seminal vesicle recurrence,
but also for the primary focus.
Conclusions
We reported a case of salvage brachytherapy for seminal
vesicle recurrence with a favorable outcome. It isOutcome Adverse event Prescribed dose
5 yr-bDFS: 87% GI: G4 (2/31) 125I:100-144 Gy
103Pd:100-120 Gy
4 yr-bDFS: 75% GU:G4 (1/17) 125I:126 Gy in principle
4 yr-bDFS: 70% GU: G3-4 13% GI: G3-4 30% 125I:137 Gy
5 yr-bDFS: 38% G3 or over: none 125I:90 Gy
3 yr-bDFS: 89.5% GU: G3 (1/24) 125I:144 Gy (108 Gy)
5 yr-FFbF: 23% lateGU: G3 (6/31)
lateGI: G3 (2/31)
125I:145 Gy
5 yr-FFbF: 64.5% GI: G4 (1/37) 125I:135 Gy
ternal Beam Radiation Therapy, Seed: Seed Implant (Brachytherapy), Neo:
al, FFbF: Freedom From biochemical Failure, GI: Gastrointestinal adverse effect,
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cant role as a salvage therapeutic modality after radi-
ation therapy including brachytherapy.
Consent
Written informed consent was obtained from the patient
to publish this case report and any accompanying im-
ages. A copy of the written informed consent is available
for review by the Editor-in-Chief of this journal.
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